HGG-TCP High Grade Glioma Tumor Concentrations of protein kinase inhibitors

Gepubliceerd: 28-08-2014 Laatst bijgewerkt: 18-08-2022

Our hypothesis is that changes in (phospho)proteomic and kinase activity profiles in tissue before and after treatment with PKIs should provide more insight into which differential markers can be clinically used to predict response to this type of...

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON28204

Bron
NTR

Verkorte titel
HGG-TCP

Aandoening

Targeted Therapy
High-grade glioma
Kinase inhibitor
Angiogenesis

Targeted therapie
Hooggradig glioom
Kinase remmer
Angiogenese

Ondersteuning

Primaire sponsor: VU University Medical Center
De Boelelaan 117, 1081 HV Amsterdam

Overige ondersteuning: fund = initiator = sponsor

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

To determine PKI and active metabolites concentrations in tumor tissue after approximately two weeks of treatment in patients with a newly diagnosed HGG.

Toelichting onderzoek

Achtergrond van het onderzoek

In clinical trials for HGG, multiple agents targeting various oncogenic signaling pathways that play an important role in the biology of HGG have been studied, but unfortunately only a small number of patients seem to benefit from these treatment strategies. Whether these disappointing results are due to a restricted drug delivery through the blood-brain barrier, or due to differential biological characteristics of these HGGs, remains unknown. To better understand these clinical observations and to find potential insight how to overcome them, we intend to measure tumor concentrations of PKIs after approximately two weeks treatment and to determine whether these tumor concentrations correlate with plasma- and CSF concentrations of PKIs. Subsequently, we intend to determine the (phospho)proteomic profiles and kinase inhibitory activity in tumor tissue from these HGG patients after approximately two weeks of treatment with a PKI.

Doel van het onderzoek

Our hypothesis is that changes in (phospho)proteomic and kinase activity profiles in tissue before and after treatment with PKIs should provide more insight into which differential markers can be clinically used to predict response to this type of targeted therapy. We will investigate the feasibility of obtaining surrogate markers for response prediction provided by comparing kinase activity and (phospho)peptide levels in tumor tissues obtained from study patients (after treatment with PKIs prior to resection) and in tumor tissues obtained from patients in a control group (without treatment with PKIs prior to resection).

Onderzoeksopzet

Patients will be treated for 2 weeks with kinase inhibitors

Onderzoeksproduct en/of interventie

Patients will be cohort-wise treated with kinase inhibitors for 2 weeks prior to surgery, which is part of standard care. During and at the end of the PKI treatment and during surgery venous bloodsamples will be taken for laboratory analysis. CSF samples will be taken for laboratory analysis during surgery.

Arm1: Drug: Sunitinib

50 mg, once daily, oral use for 14 days

Arm2: Drug: Vandetanib

300 mg, once daily, oral use for 14 days

Arm3: Drug: Erlotinib

150 mg, once daily, oral use for 14 days

Contactpersonen

Publiek

De Boelelaan 1117
H.M.W. Verheul
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4444321/300

Wetenschappelijk

De Boelelaan 1117
H.M.W. Verheul
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4444321/300

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patients without a history of brain tumor

2. Initial brain MR-scan suggesting a high grade glioma, according to the interpretation of an expert neuroradiologist

3. On initial MR-scan a tumor localisation that is deemed resectable without major neurological deficits

4. Patients must have a Karnofsky Performance Score >70%

5. Patients must have a RTOG Neurologic Function Status of 0-2

6. Patients need to have adequate hematological, renal and hepatic function as assessed by the following laboratory requirements to be conducted within seven days prior to start study treatment: - Hemoglobin > 7.0 mmol/l - Absolute neutrophil count (ANC) >1,5 x 10*9/l - Platelet count > 100 x 10*9/l - ALT and AST< 2.5 x ULN - Alkaline phosphatase < 4 x ULN - Serum creatinine eGFR > 50 ml/min

7. Patients are 18 years of older

8. Male and female patients with reproductive potential must use an approved contraceptive method during and for three months after discontinuation of study treatment

9. Patients need to give informed consent

10. Patients should be able to swallow oral medication

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Patients receiving prior chemotherapy, radiotherapy or anti-angiogenic therapy

2. Use of anti-coagulant therapy

3. Use of CYP3A4 enzyme-inducing drugs, other than dexamethasone (including Carbamazepine, Phenytoine, Phenobarbital)

4. Initial MR-scan of the brain showing tumor hemorrhage or intracerebral hemorrhage

5. Patients with progressive neurological symptoms despite dexamethasone

6. Inability to comply with protocol or study procedures

7. Pregnancy

8. Patients with uncontrolled arterial hypertension. Blood pressure must be <160/95 mmHg at the time of screening on a stable antihypertensive regimen.

9. Patients with a history of cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

10. Patients with evidence or history of bleeding diathesis

11. Patients with a history of venous or arterial thrombo-embolic events or hemorrhagic disease during the past six months

12. Patients with a history of congestive heart failure (NYHA III, IV)

13. Patients with a history of peripheral vascular disease (Fontaine stage III and IV)

14. Patients with stroke or myocardial infarction during the past six months

15. Patients with a history of a recent peptic ulcer disease (endoscopically-proven gastric ulcer, duodenal ulcer of esophageal ulcer) during the past six months

16. Patients with uncontrolled infections (> grade 2 NCI-CTC version 4.0)

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	Niet-gerandomiseerd

Controle: N.v.t. / onbekend

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-09-2014

Aantal proefpersonen:	15
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	28-08-2014
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4609
NTR-old	NTR4760
Ander register	VUmc METc : 2013.465

Resultaten